Multicentre, Single Arm, Open, Phase IV Study To Evaluate Immunogenicity And Safety Of Subcutaneous r-hIFN Beta-1a (Rebif) Using Clone 484-39 In The Treatment Of Relapsing Remitting Multiple Sclerosis

Trial Profile

Multicentre, Single Arm, Open, Phase IV Study To Evaluate Immunogenicity And Safety Of Subcutaneous r-hIFN Beta-1a (Rebif) Using Clone 484-39 In The Treatment Of Relapsing Remitting Multiple Sclerosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2014

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Merck Serono
  • Most Recent Events

    • 02 Aug 2010 Merck KGaA added as trial sponsor, trial investigator (Stubinski B) and lead centre as reported by ClinicalTrials.gov.
    • 09 Mar 2010 Actual patients number 460 added as reported by ClinicalTrials.gov.
    • 19 Dec 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top